1
|
Wigglesworth M, Lawless K, Standing D, Mackenzie E, Kitchen V, Mckay F, Ward E, Brough S, Stylianou M, Jewitt F, Mclaren-Douglas A, Jowet M, Tamayama N, Finnigan D, Ding J, Wise A. Use of Cryopreserved Cells for Enabling Greater Flexibility in Compound Profiling. ACTA ACUST UNITED AC 2008; 13:354-62. [DOI: 10.1177/1087057108317768] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Measurement of intracellular calcium release following agonist challenge within cells expressing the relevant membrane protein is a commonly used format to derive structure-activity relationship (SAR) data within a compound profiling assay. The Fluorometric Imaging Plate Reader (FLIPR) has become the gold standard for this purpose. FLIPR traditionally uses cells that are maintained in continuous culture for compound profiling of iterative chemistry campaigns. This supply dictates that assays can only be run on 4 of 5 weekdays, or alternative cell culture machinery is required such that plating can occur remotely at the weekend. The data reported here demonstrate that high-quality compound profiling data can be generated from the use of cryopreserved cells and that these cells can also be plated at various densities to generate equivalent data between 24 and 72 h post-plating. Hence, the authors report a method that allows data generation throughout the week and without the requirement of highly automated cell culture or continuous culture. ( Journal of Biomolecular Screening 2008:354-362)
Collapse
Affiliation(s)
| | | | - D.J. Standing
- Screening and Compound Profiling, GlaxoSmithKline, Harlow, UK
| | - E.K. Mackenzie
- Screening and Compound Profiling, GlaxoSmithKline, Harlow, UK
| | - V.R. Kitchen
- Screening and Compound Profiling, GlaxoSmithKline, Harlow, UK
| | - F. Mckay
- Screening and Compound Profiling, GlaxoSmithKline, Harlow, UK
| | | | - S.J. Brough
- Screening and Compound Profiling, GlaxoSmithKline, Harlow, UK
| | - M. Stylianou
- Screening and Compound Profiling, GlaxoSmithKline, Harlow, UK
| | - F.R. Jewitt
- Screening and Compound Profiling, GlaxoSmithKline, Harlow, UK
| | | | - M.I. Jowet
- Screening and Compound Profiling, GlaxoSmithKline, Harlow, UK
| | - N. Tamayama
- Biological Reagents and Assay Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK
| | - D. Finnigan
- Biological Reagents and Assay Development, GlaxoSmithKline, Stevenage, Hertfordshire, UK
| | - J. Ding
- Discovery Statistics, Upper Providence, Collegeville, PA
| | - A. Wise
- Screening and Compound Profiling, GlaxoSmithKline, Harlow, UK
| |
Collapse
|